Inicio Zine News Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease...

Roxadustat Approved in China for Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis

2
0

SAN FRANCISCO, Aug. 21, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that the National Medical Products Administration (NMPA) in China has approved expansion of the marketing authorization of roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), for the treatment of patients with anemia caused by chronic kidney disease (CKD) to include treatment in CKD patients who are not dialysis-dependent (NDD).